GlassScriptPhysician profile
Angelique Moore
NPI 1477876019
$3,763.11
in general payments reported to CMS, 2019-2025
27 companies · $710 in 2025
The $710 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,175 · 2022: $859 · 2023: $548 · 2024: $470 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $353.99 | 2021-2025 | Fintepla, Nayzilam |
| Sumitomo Pharma America, INC. | $340.07 | 2023-2025 | Aptiom, Gemtesa |
| Teva Pharmaceuticals USA, INC. | $298.81 | 2022-2025 | Uzedy, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $295.77 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $280.89 | 2023-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.07 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $247.53 | 2021 | |
| Janssen Pharmaceuticals, INC | $220.31 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $208.27 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $168.21 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.84 | 2022 | |
| Astellas Pharma US INC | $141.29 | 2021-2024 | Veozah |
| Dexcom, INC. | $129.17 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| E.R. Squibb & Sons, L.L.C. | $120.83 | 2022 | |
| Avanir Pharmaceuticals, INC. | $110.07 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $107.10 | 2023 | |
| Neurelis, INC. | $60.84 | 2023-2024 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $36.90 | 2023 | Rexulti |
| Lilly USA, LLC | $35.89 | 2025 | Mounjaro, Zepbound |
| Nestle Healthcare Nutrition INC. | $31.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $30.75 | 2021-2022 | |
| Exact Sciences Corporation | $25.16 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $21.73 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.59 | 2022 | |
| Rgh Enterprises LLC | $19.19 | 2025 | |
| Urovant Sciences INC | $17.88 | 2021 | |
| Global Blood Therapeutics, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelique Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.